Skip to Content
  • Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
  • Review
  • Open Access

18 April 2019

Cell-Free Tumour DNA as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Carcinoma

,
and
1
Department of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, Poland
2
Department of Clinical Physiology, Medical University of Lodz, Poland
*
Author to whom correspondence should be addressed.

Abstract

More than 1 million people dies worldwide due to lung cancer which is the first most incident cancer in males and the third in females. Only early diagnosis makes possible to achieve long-lasting remission or even cure the disease. Unfortunately, no tumour marker to achieve this goal has been identified, yet. One of putative lung cancer markers is free circulating tumor DNA. Its concentration seems to be related to cancer burden. Moreover, it can be subjected to mutational status analysis allowing for introduction of targeted treatment. This led to the idea of liquid biopsy which can substitute for a standard biopsy not feasible in certain clinical circumstances. Assessment of cell free tumour DNA can also inform about progression/recurrence of cancer and may have a prognostic value. Therefore, the aim of this article is to review on free circulating DNA as a potential marker in lung cancer.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.